Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Evan W Davies, Samuel Llewellyn, Amélie Beaudet, Charlotte E Kosmas, Wendy Gin-Sing & Helen A Doll. (2018) Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Preference and Adherence 12, pages 1079-1088.
Read now
Read now
Ali T Taher, John B Porter, Antonis Kattamis, Vip Viprakasit & M Domenica Cappellini. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 4073-4078.
Read now
Read now
N.C. Desai & R.D. Senta. (2015) Simultaneous Rp-HPLC determination of salicylamide, salicylic acid and deferasirox in the bulk API dosages forms. Journal of Taibah University for Science 9:2, pages 245-251.
Read now
Read now
Todd A Lee, Sarah von Riedemann & Fernando Tricta. (2014) Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature. Expert Review of Pharmacoeconomics & Outcomes Research 14:5, pages 651-660.
Read now
Read now
K. Tolley, N. Oliver, E. Miranda, K. Migliaccio-Walle, D. Bozkaya & Q. Li. (2010) Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. Journal of Medical Economics 13:3, pages 559-570.
Read now
Read now
Ali Taher & Maria Domenica Cappellini. (2009) Update on the use of deferasirox in the management of iron overload. Therapeutics and Clinical Risk Management 5, pages 857-868.
Read now
Read now
Farhan Imran & Pradyumna Phatak. (2009) Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Expert Review of Pharmacoeconomics & Outcomes Research 9:4, pages 297-304.
Read now
Read now
MD Cappellini & A Taher. (2008) Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opinion on Pharmacotherapy 9:13, pages 2391-2402.
Read now
Read now
Articles from other publishers (28)
WenBin Liu, ZhengWei Tan, YueChao Zhao, YanNa Zhao, XiaoLing Yu, BoLin Wang, FengLin Shen, Ai Mi, JinJian Lan & RuiLan Gao. (2023) Panaxadiol saponin ameliorates ferroptosis in iron-overload aplastic anemia mice and Meg-01 cells by activating Nrf2/HO-1 and PI3K/AKT/mTOR signaling pathway. International Immunopharmacology 118, pages 110131.
Crossref
Crossref
Antony P. Martin, Enrico Ferri Grazzi, Claudia Mighiu, Manoj Chevli, Farrukh Shah, Louise Maher, Anum Shaikh, Aliah Sagar, Hayley Hubberstey, Bethany Franks, Juan M. Ramos-Goñi, Mark Oppe & Derek Tang. (2022) Health state utilities for beta-thalassemia: a time trade-off study. The European Journal of Health Economics 24:1, pages 27-38.
Crossref
Crossref
Tingting Chen, Chaoxin Chen, Xin He, Jianming Guo, Maobai Liu & Bin Zheng. (2022) Fixed-dose administration and pharmacokinetically guided adjustment of busulfan dose for patients undergoing hematopoietic stem cell transplantation: a meta-analysis and cost-effectiveness analysis. Annals of Hematology 101:3, pages 667-679.
Crossref
Crossref
Louis S. Matza, Katie D. Stewart, Andrew J. Lloyd, Donna Rowen & John E. Brazier. (2021) Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value in Health 24:6, pages 812-821.
Crossref
Crossref
Asrul Akmal Shafie, Irwinder Kaur Chhabra, Jacqueline Hui Yi Wong & Noor Syahireen Mohammed. (2021) EQ-5D-3L health state utility values in transfusion-dependent thalassemia patients in Malaysia: a cross-sectional assessment. Health and Quality of Life Outcomes 19:1.
Crossref
Crossref
Louis S. Matza, L. Clark Paramore, Katie D. Stewart, Hayley Karn, Minesh Jobanputra & Andrew C. Dietz. (2019) Health state utilities associated with treatment for transfusion-dependent β-thalassemia. The European Journal of Health Economics 21:3, pages 397-407.
Crossref
Crossref
Parisa Saiyarsarai, Elahe Khorasani, Hasti Photogeraphy, Mohsen Ghaffari Darab & Meysam Seyedifar. (2020) Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran. Medicine 99:28, pages e20949.
Crossref
Crossref
Monica Hadi, Paul Swinburn, Luba Nalysnyk, Alaa Hamed & Atul Mehta. (2018) A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
M. Joseph John, Gaurav Jyani, Aikaj Jindal, Ranjeet Singh Mashon, Amrith Mathew, Shruti Kakkar, Pankaj Bahuguna & Shankar Prinja. (2018) Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major. Biology of Blood and Marrow Transplantation 24:10, pages 2119-2126.
Crossref
Crossref
Dijiong Wu, Xiaowen Wen, Wenbin Liu, Linlong Xu, Baodong Ye & Yuhong Zhou. (2017) A composite mouse model of aplastic anemia complicated with iron overload. Experimental and Therapeutic Medicine.
Crossref
Crossref
Alessia Pepe, Giuseppe Rossi, Anthony Bentley, Maria Caterina Putti, Ludovica Frizziero, Domenico Giuseppe D’Ascola, Liana Cuccia, Anna Spasiano, Aldo Filosa, Vincenzo Caruso, Aishah Hanif & Antonella Meloni. (2017) Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clinical Drug Investigation 37:5, pages 453-464.
Crossref
Crossref
Guido Crisponi, Valeria Marina Nurchi & Maria Antonietta Zoroddu. (2014) Iron Chelating Agents for Iron Overload Diseases. Thalassemia Reports 4:2, pages 2046.
Crossref
Crossref
Nick Adlard, Philip Kinghorn & Emma Frew. (2014) Is the UK NICE “Reference Case” Influencing the Practice of Pediatric Quality-Adjusted Life-Year Measurement within Economic Evaluations?. Value in Health 17:4, pages 454-461.
Crossref
Crossref
Winfred C Wang & Kerry Dwan. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Anthony Bentley, Samantha Gillard, Michael Spino, John Connelly & Fernando Tricta. (2013) Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective. PharmacoEconomics 31:9, pages 807-822.
Crossref
Crossref
Ali Keshtkaran, Mehdi Javanbakht, Sedigheh Salavati, Atefeh Mashayekhi, Mehran Karimi & Bijan Nuri. (2013) Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Transfusion 53:8, pages 1722-1729.
Crossref
Crossref
Jonathan Karnon, Keith Tolley, Joao Vieira & David Chandiwana. (2012) Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload. Clinical Drug Investigation 32:12, pages 805-815.
Crossref
Crossref
L. B. Jordan, F. Vekeman, A. Sengupta, M. Corral, A. Guo & M. S. Duh. (2012) Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. Journal of Clinical Pharmacy and Therapeutics 37:2, pages 173-181.
Crossref
Crossref
Nantasit Luangasanatip, Nathorn Chaiyakunapruk, Nilawan Upakdee & Peerapon Wong. (2011) Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in Thailand. Clinical Drug Investigation 31:7, pages 493-505.
Crossref
Crossref
Manuel Muñoz, José Antonio García-Erce & Ángel Francisco Remacha. (2011) Disorders of iron metabolism. Part II: iron deficiency and iron overload. Journal of Clinical Pathology 64:4, pages 287-296.
Crossref
Crossref
Heather A. Leitch. (2011) Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes. Drugs 71:2, pages 155-177.
Crossref
Crossref
R.H.B. Meyboom. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
465
478
.
Pattara Leelahavarong, Usa Chaikledkaew, Suradej Hongeng, Vijj Kasemsup, Yoel Lubell & Yot Teerawattananon. (2010) A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Services Research 10:1.
Crossref
Crossref
Aryeh Shander & Kathleen Sazama. (2010) Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 50:5, pages 1144-1155.
Crossref
Crossref
Jinhyun Kim & Younhee Kim. (2009) A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea. Value in Health 12, pages S78-S81.
Crossref
Crossref
David P. Steensma. (2009) Myelodysplasia paranoia: Iron as the new radon. Leukemia Research 33:9, pages 1158-1163.
Crossref
Crossref
Federica PiloAnna Angela Di TucciLaura DessìEmanuele Angelucci. (2009) Management of Transfusional Chronic Iron Overload: Focus on Deferasirox. Clinical Medicine. Therapeutics 1, pages CMT.S1970.
Crossref
Crossref
. (2013) Deferasirox dominates deferoxamine for iron control. PharmacoEconomics & Outcomes News 556:1, pages 5-5.
Crossref
Crossref